Matinas BioPharma Holdings, Inc. (MTNB) does not have a usable analyst price target set. The company is a clinical-stage biopharmaceutical firm in the middle of a strategic wind-down and reverse-merger, and sell-side coverage has effectively evaporated. Third-party trackers still display conflicting, stale figures—an average near $0.65 from two analysts with a $0.30–$1.00 range on one platform, and a single headline consensus near $3.00 on another—but these predate the company's 2026 restructuring and a reverse stock split, and they sit both above and below the current share price.
Because no group of current, attributable analyst targets exists, the $2.50 objective used here is a fallback drawn from public trading data rather than analyst consensus. In late September 2026, shortly after the company's reverse split, shares traded near $2.48. That level, not an analyst estimate, anchors the $2.50 figure discussed throughout this article.
As of early November 2026, MTNB traded near $1.24, with a 52-week range of roughly $0.97 to $19.95 and a market capitalization of only about $1.2 million. Reaching $2.50 from $1.24 implies a gain of approximately 102%—a very large move.
Matinas announced in July 2026 a definitive business combination with GH Power, a critical-minerals and clean-energy developer whose modular reactors convert recycled metals and water into high-purity alumina, green hydrogen, and thermal energy. Under the plan, existing Matinas stockholders would own about 9% of the newly formed GH Power International, with each Matinas share converting into 0.1 of a GH Power share. Separately, Matinas agreed to sell its lipid nanocrystal (LNC) platform and lead candidate MAT2203 to Azurity Pharmaceuticals for $4 million upfront plus up to $17.5 million in milestones and mid-single-digit royalties.
Completion of the GH Power combination would reposition MTNB from a cash-burning biotech into a listed clean-energy and critical-materials company, a catalyst that could reframe how the market values the shares. The Azurity sale provides near-term cash and potential milestone and royalty upside. The stock's own recent history—trading near $2.48 just weeks after the reverse split—demonstrates that the $2.50 area is a level the shares have already reached, and micro-cap names with very low float can produce sharp, rapid price swings on relatively little volume.
The obstacles are substantial. Matinas generates no meaningful revenue and reported a trailing-twelve-month net loss of about $7.3 million, with total cash of only about $0.76 million, leaving it dependent on financing. The combination carries multiple closing conditions—shareholder and court approvals, an effective registration statement, at least $15 million in new financing, and NYSE American listing—and either party can terminate if the deal has not closed by December 31, 2026. Convertible preferred stock and warrants exercisable at $0.35 create additional dilution risk, and the stock's extreme volatility, illiquidity, and reverse-split history add further uncertainty.
The 52-week range of roughly $0.97 to $19.95 reflects the turbulence of a reverse split and corporate restructuring. Near $1.24, the stock sits in the lower portion of that range, with the roughly $2.48 post-split level acting as a nearby overhead reference and $1.00 serving as a psychological support zone below. Given the tiny market capitalization and thin trading, technical levels are less reliable here than the binary, event-driven question of whether the transaction completes.
There is no analyst research horizon to rely on; the practical timeline is governed by the business combination, which the parties have said they expect to close in the fourth quarter of 2026. Investors should watch for the proxy statement and Form F-4 filing, the shareholder vote, Ontario court approval, completion of the minimum $15 million financing, and confirmation of the GHP International listing. Any delay, renegotiation, or termination of the deal would directly reshape the outlook for the shares.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, thinly traded micro-cap such as MTNB, these automated signals can help traders spot shifting trends, monitor positions, and screen for opportunities more efficiently than manual review. Traders looking to stay ahead of rapid moves can explore the AI Daily Buy/Sell Signals to see how the system is reading current conditions.
Can MTNB reach $2.50? The target is not an analyst forecast—there is no current analyst coverage—but rather a fallback anchored to the stock's own recent post-split trading level near $2.48. From a price near $1.24, the required move of roughly 102% is very large, and the path depends almost entirely on the GH Power business combination and the Azurity divestiture proceeding to completion. Those catalysts could reframe the company's valuation, while the tiny cash balance, continued losses, dilution, and execution risk could just as easily keep shares depressed. Investors should treat $2.50 as a reference point tied to recent trading, not a forecast, and monitor the transaction milestones closely.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, MTNB has been loosely correlated with SPRC. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if MTNB jumps, then SPRC could also see price increases.
| Ticker / NAME | Correlation To MTNB | 1D Price Change % | ||
|---|---|---|---|---|
| MTNB | 100% | -0.81% | ||
| SPRC - MTNB | 35% Loosely correlated | -8.78% | ||
| AXON - MTNB | 34% Loosely correlated | -0.21% | ||
| VKTX - MTNB | 32% Poorly correlated | -1.14% | ||
| MDGL - MTNB | 31% Poorly correlated | -0.04% | ||
| DCOY - MTNB | 29% Poorly correlated | -0.90% | ||
More | ||||